Impact of computerized pre-authorization of broad spectrum antibiotics in Pseudomonas aeruginosa at a children's hospital in Japan

Journal of Infection and Chemotherapy

Volumn 22, Issue 8, 2016, Pages 532-535

  Horikoshi, Yuho ^a   Higuchi, Hiroshi ^a   Suwa, Junichi ^a   Isogai, Mihoko ^a   Shoji, Takayo ^b   Ito, Kenta ^a  

^a TOKYO METROPOLITAN CHILDREN'S MEDICAL CENTER   (Japan)

^b SHIZUOKA CHILDREN'S HOSPITAL   (Japan)

Author keywords

Antimicrobial stewardship program; Carbapenems; Children's hospital; Pre authorization; Pseudomonas aeruginosa; Resistant organism

Indexed keywords

CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL STEWARDSHIP PROGRAM; ARTICLE; AUTOMATION; DRUG COST; DRUG PROGRAM; HUMAN; JAPAN; LENGTH OF STAY; MORTALITY; PEDIATRIC HOSPITAL; PRESCRIPTIVE AUTHORITY; PSEUDOMONAS AERUGINOSA; ANALOGS AND DERIVATIVES; DRUG EFFECTS; HOSPITAL; MICROBIAL SENSITIVITY TEST; PSEUDOMONAS INFECTIONS;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CARBAPENEMS; CEFTAZIDIME; CEPHALOSPORINS; HOSPITALS; HUMANS; JAPAN; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PIPERACILLIN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TOKYO;

EID: 84976545088     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2016.05.001     Document Type: Article

References (14)

1. [1] WHO, Antimicorbial resistance: global report on surveilalance., 2014, World Health Organization, Geneva.
2. [2] Tansarli, G.S., Karageorgopoulos, D.E., Kapaskelis, A., Falagas, M.E., Impact of antimicrobial multidrug resistance on inpatient care cost: an evaluation of the evidence. Expert Rev Anti Infect Ther 11 (2013), 321–331.
3. [3] Neidell, M.J., Cohen, B., Furuya, Y., Hill, J., Jeon, C.Y., Glied, S., et al. Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. Clin Infect Dis 55 (2012), 807–815.
4. [4] Lambert, M.L., Suetens, C., Savey, A., Palomar, M., Hiesmayr, M., Morales, I., et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. Lancet Infect Dis 11 (2011), 30–38.
5. [5] Zheng, Y.L., Wan, Y.F., Zhou, L.Y., Ye, M.L., Liu, S., Xu, C.Q., et al. Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia. Am J Infect Control 41 (2013), e59–63.
6. [6] Liu, Q., Li, W., Du, X., Zhong, T., Tang, Y., Feng, Y., et al. Risk and prognostic factors for multidrug-resistant acinetobacter baumannii complex bacteremia: a retrospective study in a Tertiary Hospital of West China. PLoS One, 10, 2015, e0130701.
7. [7] Ng, T.M., Teng, C.B., Lye, D.C., Apisarnthanarak, A., A multicenter case-case control study for risk factors and outcomes of extensively drug-resistant Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 35 (2014), 49–55.
8. [8] Yamaguchi, K., Ishii, Y., Tateda, K., Iwata, M., Watanabe, N., Shinagawa, M., et al. Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2012. Jpn J Antibiot 67 (2014), 73–107.
9. [9] Delory, T., De Pontfarcy, A., Emirian, A., About, F., Berdougo, B., Brun-Buisson, C., et al. Impact of a program combining pre-authorization requirement and post-prescription review of carbapenems: an interrupted time-series analysis. Eur J Clin Microbiol Infect Dis 32 (2013), 1599–1604.
10. [10] Horikoshi Y, Suwa J, Higuchi H, Miyairi I. Antimicrobial stewardship program in pediatric health care facilities in Japan (abstract in Japanese). In: 46th annual meeting of Japanese society for pediatric infectious diseases; Tokyo, October 18-19, 2014. Tokyo: Japanese society for Pediatric Infectious Diseases; 2014.
11. [11] Burke, J.P., Antibiotic resistance—squeezing the balloon?. JAMA 280 (1998), 1270–1271.
12. [12] Di Pentima, M.C., Chan, S., Hossain, J., Benefits of a pediatric antimicrobial stewardship program at a children's hospital. Pediatrics 128 (2011), 1062–1070.
13. [13] Tamma, P.D., Robinson, G.L., Gerber, J.S., Newland, J.G., DeLisle, C.M., Zaoutis, T.E., et al. Pediatric antimicrobial susceptibility trends across the United States. Infect Control Hosp Epidemiol 34 (2013), 1244–1251.
14. [14] Bumpass, J.B., McDaneld, P.M., DePestel, D.D., Lamp, K.C., Chung, T.J., McKinnon, P.S., et al. Outcomes and metrics for antimicrobial stewardship: survey of physicians and pharmacists. Clin Infect Dis 3 (2014), S108–S111.